Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The Effects of NT-1044, a Novel AMPK Activator, on Endometrial Cancer Cell Proliferation, Apoptosis, Cell Stress and In Vivo Tumor Growth.

Autor: Roque DR; Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Zhang L; Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China., Wysham WZ; Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Han J; Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China., Sun W; Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Yin Y; Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Livingston JN; NovaTarg Therapeutics, First Flight Venture Center, Durham, NC, United States., Batchelor KW; NovaTarg Therapeutics, First Flight Venture Center, Durham, NC, United States., Zhou C; Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Bae-Jump VL; Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2021 Aug 05; Vol. 11, pp. 690435. Date of Electronic Publication: 2021 Aug 05 (Print Publication: 2021).

Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.

Autor: Frye SV; Glaxo Inc. Research Institute, Research Triangle Park, North Carolina 27709, USA., Haffner CD, Maloney PR, Hiner RN, Dorsey GF, Noe RA, Unwalla RJ, Batchelor KW, Bramson HN, Stuart JD, et. al.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 1995 Jul 07; Vol. 38 (14), pp. 2621-7.